Cancer research
Research led by Tao Liu of Capital Medical University has made a groundbreaking discovery in the field of cancer gene therapy, elucidating the role of the MDM2-GPX4-ferroptosis regulatory axis in intracerebral hemorrhage. This research holds promise for identifying new therapies for this condition, which is characterized by bleeding in the
Cancer research
A recent study by researchers from the Cancer Hospital in Beijing, China, highlights the pivotal year 2024 as a significant turning point for therapeutic breakthroughs in human diseases, particularly in cell and gene therapies (CGTs). According to the study, 2024 saw the approval of 13 novel CGTs by the US
Genetic research
Researchers from the First Affiliated Hospital of Zhejiang Chinese Medical University conducted a study on the anticancer properties of luteolin, a natural flavonoid, in colon cancer. The findings reveal that luteolin induces ferroptosis, a process of programmed cell death, and enhances immune activation in colon cancer cells. The study aimed
Genetic research
Research from the Postgraduate Institute of Medical Education and Research in Chandigarh, India, has highlighted the critical role of long non-coding RNAs (lncRNAs) and autophagy in the progression of hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality worldwide. According to the study, lncRNAs modulate autophagy through mechanisms such as
Cancer research
Researchers from the Petru Poni Institute of Macromolecular Chemistry in Romania have made a significant discovery in the field of cancer gene therapy. They have developed a dual-functional nanoplatform, named carbon dot-enhanced doxorubicin liposomes, which has shown remarkable synergistic antitumor activity. This innovative approach combines the therapeutic effects of doxorubicin,
Genetic research
Paediatricians play a critical role in recognising and managing inherited eye disorders in children, which can cause significant vision impairment. Recent advances in ocular genetic therapy and clinical trials offer new hope for patients. A practical guide has been developed to help paediatricians navigate these conditions, including identifying common Mendelian
Cancer
Research from Amrita Vishwa Vidyapeetham in Kerala, India, suggests that liposomes, lipid carriers, may hold the key to delivering therapeutic advantages in treating pediatric neurological disorders such as epilepsy, migraine, autism, ADHD, and brain tumors. These tiny vesicles can cross the blood-brain barrier, allowing for controlled drug delivery and minimizing
Genetic research
Researchers from the Royal Melbourne Institute of Technology - RMIT University have made a groundbreaking discovery in the field of gene therapy, introducing a novel method for overcoming endosomal escape limitations in drug delivery. Led by Calum J. Drummond, the team has developed cubic phase lipid nanoparticles (cubosomes) that can
Cancer
Researchers at Central South University have published a comprehensive review on the mechanisms of immune evasion in cancer and potential therapeutic approaches. The review highlights the complex processes by which tumors evade immune surveillance, including tumor-induced immune suppression, immune checkpoint regulation, and genetic and epigenetic influences. The study also emphasizes
Cancer
A team of researchers from the University Grenoble-Alpes has made significant advancements in the field of biotechnology, particularly in cancer gene therapy. Their study, published in the European Journal of Pharmaceutical Sciences, explores the potential of photodynamic drug delivery systems in cancer treatment. The researchers propose a novel approach using
Cancer
Genprex, a clinical-stage gene therapy company, has been granted patents for its lead drug candidate, Reqorsa, in combination with PD-L1 and PD-1 antibodies by the U.S. Patent and Trademark Office and the European Patent Office. These patents will expire in 2037 at the earliest, providing Genprex with intellectual property
Cancer
Genprex, Inc. has announced that it has received a Notice of Allowance for a patent covering the use of its lead drug candidate, Reqorsa Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq. This patent will expire in 2037 at the earliest. The company has also been granted patents
